Promising Developments and Strategic Initiatives Drive Buy Rating for BioNTech SE

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on May 14.

Robert Burns has given his Buy rating due to a combination of factors that highlight BioNTech SE’s promising future developments and strategic initiatives. One of the key reasons is the anticipated presentation of numerous datasets at the ASCO 2025 conference, which includes data from various clinical trials involving BNT327, a potential backbone agent for multiple indications. The unique targeting mechanism of BNT327, which utilizes PD-L1 instead of PD-1, may offer a safety advantage, potentially making it a more favorable option in oncology treatments.
Additionally, BioNTech’s combination strategy has shown promising results, particularly in preclinical studies and early clinical trials. The combination of BNT327 with other ADCs in their pipeline has demonstrated superior anti-tumor effects compared to individual treatments. Notably, the combination of BNT327 and BNT325 in patients with late-line ovarian cancer showed a comparable objective response rate to existing treatments. These developments suggest significant potential for BioNTech’s oncology pipeline, supporting the Buy rating.

In another report released on May 14, Bank of America Securities also reiterated a Buy rating on the stock with a $127.00 price target.